Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
Recruiting · NCT05559879 · Registry updated 2026-04-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, carcinoma, endometrium neoplasm, epithelial neoplasm, female reproductive organ cancer, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine cancer, uterine disorder | Recruiting | Phase 1 / Phase 2 | 2026-04-15 | NCT05559879 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| University of Alabama at Birmingham | 467 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| O'Neal Comprehensive Cancer Center at UAB | Birmingham | United States | 3 |